Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is the most frequently occurring type of lymphoid malignancy in adults worldwide. It arises from normal antigen-exposed B cells which have migrated to germinal centers in secondary lymphoid organs ([@b1-mmr-16-04-3777]). DLBCL is a clinically heterogeneous disease and \~40% of patients may be cured by anthracycline-based chemotherapy ([@b2-mmr-16-04-3777]). Therefore, the early diagnosis and treatment of DLBCL is critical.

A previous study indicated that specific genetic and epigenetic cancer characteristics were detectable in the plasma, serum and tissue of patients, and these were able to be used for the early detection and diagnosis of cancer ([@b3-mmr-16-04-3777]). Ten-Eleven Translocation (TET) hydroxylases are able to convert 5-methylcytosine to 5-hydroxymethylcytosine and induce DNA demethylation ([@b4-mmr-16-04-3777]). The use of a mutation screening assay and the genome-wide profiling has verified that TET2 mutations may result in the aberrant methylation of various genes ([@b5-mmr-16-04-3777]). Microarray technology has contributed to the development of life sciences, making it possible to obtain large quantities of genes, microRNAs, or DNA methylated sites for further analysis of cancer at the molecular level ([@b6-mmr-16-04-3777],[@b7-mmr-16-04-3777]). In addition, combining microarray data and statistical methods may be used to detect influential genes in cancers ([@b8-mmr-16-04-3777]). Although TET mutations were considered to be associated with DLBCL, the mechanism of DNA methylation in DLBCL remains to be elucidated. Novel diagnostic targets and treatment strategies for this disease are urgently required and of primary concern.

The present study compared the data from the DNA methylation and gene expression profiles in TET2 mutated samples, with TET2 wild-type samples, and differentially expressed genes (DEGs) and differentially methylated regions (DMRs) were identified. Following this, functional and pathway analyses were conducted and various key genes and pathways associated with DLBCL and TET2 mutations were identified.

Materials and methods
=====================

### Microarray data

The gene expression profile of GSE37365 was downloaded from the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)) and deposited by Asmar *et al* ([@b5-mmr-16-04-3777]). It contained two subseries: the genome-wide gene expression dataset GSE37362 and the DNA methylation microarray dataset GSE37363. In GSE37362, there were 12 human DLBCL biopsy tissues with TET2 mutations and 19 TET2 wild-type DLBCL biopsy tissues, and the dataset was performed on the Illumina HumanMethylation450 BeadChip (GPL13534) platform (Illumina, San Diego, CA, USA). The gene expression dataset (GSE37363) contained 4 human DLBCL biopsy tissues with TET2 mutations and 5 TET2 wild-type DLBCL biopsy tissues and was detected with Affymetrix Human Gene 1.0 ST Array (GPL6244) platform (Affymetrix, Inc., Santa Clara, CA, USA).

### Data preprocessing

The original CEL gene microarray data were imported into *R* and the Affy package (<http://bioconductor.org/packages/release/bioc/html/affy.html>) was used for the background correction and robust multi array normalization ([@b9-mmr-16-04-3777]). The probe-level symbols were converted into gene-level symbols. If multiple probes corresponded to one gene symbol, the average expression value of all probes was defined as the gene expression value. For the DNA methylation dataset, the IMA package (<https://www.rforge.net/IMA>) of *R* was used to normalize the methylation level in each methylation site. The methylation sites located in the X and Y chromosomes or SNPs were removed. P-value \<0.05 was set as the cut-off criterion for the DNA-methylation matrix.

### Differential expression analysis

DEGs were identified by the limma package (<http://bioconductor.org/packages/release/bioc/html/limma.html>) ([@b10-mmr-16-04-3777]) of *R* in TET2 mutated DLBCL samples compared with wild-type samples, according to the thresholds of Benjamini-Hochberg (BH) adjusted P-value \<0.05 and \|log2 (fold change)\| \>1. A total of 3 differentially methylated levels were identified. The first one was obtained by the P-value of a Student\'s t-test (P\<0.05) in *R* ([www.r-project.org](www.r-project.org)) and the β value of the DNA methylation site in TET2 mutated samples compared with wild-type samples. The second one was determined by the gene regions, including the first exon area (EXON1), 1--200 bp upstream of the transcription start site (TSS200), 1--1500 bp upstream of the transcription start site (TSS1500), 3′-untranslated region (UTR) and 5′UTR. The third one was calculated by the locational data involving the CpG island, 1--200 bp upstream of the CpG island (N-CPGshore), 200--400 bp upstream of the CpG island (N-CPGshelf), 1--200 bp downstream of the CpG island (S-CPGshore) and 200--400 bp downstream of the CpG island (S-CPGshelf). Finally, with \|∆β\| \>0.1 and P-value \<0.05, the differentially methylated sites (DMSs) and DMRs were selected out in TET2 mutated samples and compared with wild-type samples.

The DMSs and DMRs were transformed to target genes termed differentially methylated genes (DMGs) using the annotation information, and the overlapping genes between the identified DMGs and DEGs were obtained.

### Functional enrichment analysis

The biological process (BP) of Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for the aforementioned screened genes were identified using GOstats (<http://www.bioconductor.org/packages/release/bioc/html/GOstats.html>) ([@b11-mmr-16-04-3777]) and GSEABase packages (<http://www.bioconductor.org/packages/release/bioc/html/GSEABase.html>) ([@b12-mmr-16-04-3777]), respectively. The adjusted P-value \<0.01 was selected as the cut-off criterion. The network of enriched pathways was constructed using the Pathview package (<http://www.bioconductor.org/packages/release/bioc/html/pathview.html>) ([@b13-mmr-16-04-3777]).

Results
=======

### Screening of DEGs and DMGs

The raw data were normalized in all samples and are presented in [Fig. 1](#f1-mmr-16-04-3777){ref-type="fig"}. A total of 198 DEGs (106 up- and 92 downregulated) were identified in TET2 mutated DLBCL samples compared with wild-type samples and the top 30 DEGs are listed in [Table I](#tI-mmr-16-04-3777){ref-type="table"}. A total of 10493 DMSs, distributed over 3768 genes with \|∆β\| \>0.1 and P-value \<0.05 (group 1) were screened. A total of 1411 non-redundant genes (group 2) were selected from the DMRs ([Fig. 2](#f2-mmr-16-04-3777){ref-type="fig"}). As presented, the majority of DMRs were located in the gene body accounting for 26.5%, followed by TSS1500 with 20.2%. A further 1670 non-redundant genes (group 3) were identified by their location, of which 51.9% genes were located in CpG islands, 15.5% in N-shore, 12.1% in S-shore, 1.63% in N-shelf and 1.49% in S-shelf ([Fig. 3](#f3-mmr-16-04-3777){ref-type="fig"}). The results revealed that 602 DMGs were shared among the three groups. In addition, 12 overlapping genes, cryptochrome circadian clock (CRY)1, cytochrome B5 reductase (CYB5R) 2, doublecortin like kinase (DCLK) 2, fibronectin 1, glutathione peroxidase 3, short chain dehydrogenase/reductase family 42E, member 1 (SDR42E1), secreted frizzled related protein 2, spi-B transcription factor (SPIB), zinc finger protein (ZNF) interacting with K protein (ZIK) 1, ZNF134, ZNF256 and ZNF615 were identified in the 198 DEGs and 602 DMGs.

### Enriched GO terms and KEGG pathways of key target genes

It was demonstrated that 9 of the 12 overlapped genes were downregulated and hypermethylated, including *CRY1, CYB5R2, DCLK2, SDR42E1, SPIB, ZIK1, ZNF134, ZNF256* and *ZNF615*. The heatmap of these 9 genes is presented in [Fig. 4](#f4-mmr-16-04-3777){ref-type="fig"}. Furthermore, using the cut-off criterion of P-value \<0.01, 24 BPs of GO terms were obtained, including organic cyclic compound biosynthetic process (P=0.000131518), blue light signaling pathway (P=0.001212284) and cellular response to blue light (P=0.001212284; [Table II](#tII-mmr-16-04-3777){ref-type="table"}). A significant KEGG pathway associated with circadian rhythm was obtained ([Fig. 5](#f5-mmr-16-04-3777){ref-type="fig"}).

Discussion
==========

TET2, one of the three proteins of the TET family, catalyzes the conversion of 5-methyl-cytosine to 5-hydroxymethyl-cytosine and promotes DNA demethylation ([@b14-mmr-16-04-3777]). The present study, by using the data reported by Asmar *et al* ([@b5-mmr-16-04-3777]), analyzed the DNA methylation and gene expression profiles in TET2 mutated samples compared with wild-type samples.

DNA methylation is one of the most common epigenetic modifications which may regulate gene expression in mammalian cells ([@b15-mmr-16-04-3777]). Abnormal DNA methylation may lead to tumor formation and development ([@b16-mmr-16-04-3777],[@b17-mmr-16-04-3777]). DLBCL represents the most frequently occurring B-cell malignancy with a high mortality rate, with a rapid progression and fatal outcome ([@b18-mmr-16-04-3777]). It has previously been demonstrated that abnormal DNA methylation is associated with the pathogenesis and development of DLBCL. Shaknovich *et al* ([@b19-mmr-16-04-3777]) reported that methylation of Src homology region 2 domain-containing phosphatase (SHP) 1 is frequently detected in plasma and tissues of DLBCL patients and therefore methylation of SHP1 may serve as a candidate biomarker for DLBCL. Additionally, TET mutations are typically observed in early hematopoietic progenitors ([@b20-mmr-16-04-3777]) and it was hypothesized that they resulted in gene aberrant methylation in hematopoietic development ([@b5-mmr-16-04-3777]). In the present study, 198 DEGs and 602 DMGs were identified and 9 genes CRY1, CYB5R2, DCLK2, SDR42E1, SPIB, ZIK1, ZNF134, ZNF256 and ZNF615 were revealed to be downregulated and hypermethylated in the TET2 mutated DLBCL samples compared with wild-type samples. The results demonstrated that CRY1, a gene associated with the circadian system ([@b21-mmr-16-04-3777]), was significantly enriched in the circadian rhythm pathway. CRY1 and CRY2, interact with the period circadian clock (PER) proteins, and have a role in the negative limbs of the clock feedback loop ([@b22-mmr-16-04-3777]). Circadian rhythms control a variety of metabolic and physiological functions, and abnormal circadian rhythms may be directly associated with the development of cancer ([@b23-mmr-16-04-3777]). A previous study demonstrated that the downregulated clock gene PER2 in DLBCL patients was targeted by the transcription factor (CCAAT/enhancer-binding protein α and *PER2* may act as a tumor suppressor gene ([@b24-mmr-16-04-3777]). In addition, the epigenetic inactivation of aryl hydrocarbon receptor nuclear translocator-like protein (BMAL) 1, another circadian clock gene, has been revealed to contribute to the development of hematologic malignancies ([@b25-mmr-16-04-3777]). Furthermore, *CRY1* may modulate the ATR-mediated DNA damage checkpoint response by interacting with the timeless gene ([@b26-mmr-16-04-3777]). The role of CRY1 as a key gene in the association between DLBCL and TET mutations has previously been investigated.

Furthermore, it was noted that \~50% of the aforementioned 9 genes encoded zinc finger proteins, including ZIK1, ZNF134, ZNF256 and ZNF615. Consistent with Asmar *et al* ([@b5-mmr-16-04-3777]), ZIK1 was hypermethylated and downregulated in the results of the present study. Numerous studies have reported an association between zinc finger proteins and lymphoma or lymphatic disease. Bond *et al* ([@b27-mmr-16-04-3777]) suggests that early hematopoietic zinc finger proteins are important in the regulation of human hematopoiesis and may be associated with the development of hematopoietic malignancies. Möröy *et al* ([@b28-mmr-16-04-3777]) suggests that zinc finger protein growth factor independent 1 transcriptional repressor may maintain development and progression of lymphoid leukemia by suppressing the activation of the tumor suppressor p53. This suggests that different zinc finger proteins serve different roles in various types of cancer. Therefore, it was hypothesized that ZIK1, ZNF134, ZNF256 and ZNF615 may be involved in the development of DLBCL with TET2 mutations. Further validation of these genes is required.

In conclusion, the results of the present study suggested that the genes which were hypermethylated and downregulated in DLBCL biopsy tissues with TET2 mutations, exhibited important roles in the development of DLBCL. These genes, including CRY1, ZIK1, ZNF134, ZNF256 and ZNF615, may be affected by TET mutations and may act as potential biomarkers for the early diagnosis, therapy and prognosis of DLBCL. However, further experiments are required in order to validate the specific function of these genes in DLBCL.
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![Boxplots for microarrays (A) prior to and (B) following application of normalization. Red boxes represent TET mutated diffuse large B-cell lymphoma samples. Blue boxes represent TET2 wild-type samples. TET, Ten-Eleven Translocation hydroxylases.](MMR-16-04-3777-g00){#f1-mmr-16-04-3777}

![The distributions of differentially methylated genes based on the genetic regions. UTR, untranslated region; TSS, transcription start site.](MMR-16-04-3777-g01){#f2-mmr-16-04-3777}
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![Hierarchical clustering heatmap of CRY1, CYB5R2, DCLK2, SDR42E1, SPIB, ZIK1, ZNF134, ZNF256 and ZNF615. Each column corresponds to a single microarray and each row represents expression profile of a single gene. Red and blue represent the low and high values of the gene expression, respectively. Case-1, 2, 3, 4 represent human DLBCL biopsy tissue samples with TET mutations and control-1, 2, 3, 4, 5, represent TET2 wild-type DLBCL biopsy tissue samples. DLBCL, diffuse large B-cell lymphoma; TET, Ten-Eleven Translocation hydroxylases; CRY1 cryptochrome circadian clock 1; CYB5R2, cytochrome B5 reductase 2; DCLK2, doublecortin like kinase; SDR42E1, short chain dehydrogenase/reductase family 42E, member 1; SPIB, spi-B transcription factor; ZNF, zinc finger protein; ZIK1, ZNF interacting with K protein.](MMR-16-04-3777-g03){#f4-mmr-16-04-3777}

![Pathway of circadian rhythm. The red gene is the significant gene involved in the pathway. CRY1 cryptochrome circadian clock 1; KEGG, kyoto encyclopedia of genes and genomes; CREB1, CAMP responsive element binding protein 1; MAPK, mitogen activated protein kinase; Fbx 13, F-box 13; Ror, RAR related orphan receptor; PER, period circadian clock; Cklε, casein kinase 1 ε; Cklδ, casein kinase 1δ; SCF, Skp1-Cul1-F-box protein; β-TrCP, β-transducin repeat containing E3 ubiquitin protein ligase.](MMR-16-04-3777-g04){#f5-mmr-16-04-3777}

###### 

The top 30 DEGs in TET2 mutated DLBCL samples compared with wild-type samples.

  Gene         LogFC      P-value
  ------------ ---------- -------------
  ZIK1         −1.00204   5.43×10^−5^
  SLC9A7       −2.12435   8.30×10^−5^
  FAM129C      −1.78254   0.000152
  VCAN         1.888421   0.000272
  ZNF256       −2.00847   0.00029
  ZNF542P      −1.48907   0.000365
  RNU2-6P      −2.03556   0.00037
  KIAA0226L    −3.08868   0.000435
  VDR          1.206615   0.000439
  IFT57        −1.36341   0.00056
  APOBEC3B     2.477052   0.000594
  ZNF667-AS1   −2.00769   0.000808
  SERPINB9     1.405557   0.001202
  SDR42E1      −1.28485   0.001228
  BCL2         −1.23809   0.001266
  KCNN3        1.915499   0.001271
  ZNF350       −1.70697   0.001372
  PRRG4        1.080011   0.001556
  SLC7A11      2.276444   0.001604
  CEP68        −1.00705   0.001643
  SPP1         3.186619   0.001661
  ZNF382       −1.46886   0.00197
  EMP1         1.098811   0.001994
  PLA2G2A      1.148008   0.002013
  GPR183       −2.03511   0.002126
  PDGFRA       2.247303   0.002385
  CHPF         1.078177   0.002536
  CRY1         −1.08059   0.00269
  LZTFL1       −1.77782   0.002797
  AKT3         −1.13853   0.002883

DEGs, differentially expressed genes; TET, Ten-Eleven Translocation; DLBCL, diffuse large B-cell lymphoma; LogFC, log (fold change).

###### 

Significant 24 GO terms for screened genes.

  GO term      Description                                                      P-value       Genes
  ------------ ---------------------------------------------------------------- ------------- -------------------------------------------------------------
  GO:1901362   Organic cyclic compound biosynthetic process                     0.000131518   *CRY1, SPIB, ZNF134, ZNF256, CYB5R2, SDR42E1, ZIK1, ZNF615*
  GO:0009785   Blue light signaling pathway                                     0.001212284   *CRY1*
  GO:0071483   Cellular response to blue light                                  0.001212284   *CRY1*
  GO:1901576   Organic substance biosynthetic process                           0.001486849   *CRY1, SPIB, ZNF134, ZNF256, CYB5R2, SDR42E1, ZIK1, ZNF615*
  GO:0009058   Biosynthetic process                                             0.00165506    *CRY1, SPIB, ZNF134, ZNF256, CYB5R2, SDR42E1, ZIK1, ZNF615*
  GO:0009637   Response to blue light                                           0.001817937   *CRY1*
  GO:1901360   Organic cyclic compound metabolic process                        0.00276577    *CRY1, SPIB, ZNF134, ZNF256, CYB5R2, SDR42E1, ZIK1, ZNF615*
  GO:0006355   Regulation of transcription, DNA-dependent                       0.002884379   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:2001141   Regulation of RNA biosynthetic process                           0.002991969   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0006694   Steroid biosynthetic process                                     0.003173823   *CYB5R2, SDR42E1*
  GO:0051252   Regulation of RNA metabolic process                              0.003375671   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:2000112   Regulation of cellular macromolecule biosynthetic process        0.004585358   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0006351   Transcription, DNA-dependent                                     0.004971651   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0010556   Regulation of macromolecule biosynthetic process                 0.005245834   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0032774   RNA biosynthetic process                                         0.005738022   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0031326   Rregulation of cellular biosynthetic process                     0.006573337   *CRY1, SPIB, ZNF134, ZNF256, ZIK1*,
  GO:0009889   Regulation of biosynthetic process                               0.006882303   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0010468   Regulation of gene expression                                    0.006955993   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0019219   Regulation of nucleobase-containing compound metabolic process   0.007355736   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0018298   Protein-chromophore linkage                                      0.007856527   *CRY1*
  GO:0051171   Regulation of nitrogen compound metabolic process                0.008353762   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0034654   Nucleobase-containing compound biosynthetic process              0.008928906   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0018130   Heterocycle biosynthetic process                                 0.009820777   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*
  GO:0019438   Aromatic compound biosynthetic process                           0.009834588   *CRY1, SPIB, ZNF134, ZNF256, ZIK1, ZNF615*

GO, Gene Ontology.
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